The Cigna Group’s (CI) “Overweight” Rating Reiterated at Cantor Fitzgerald

The Cigna Group (NYSE:CI)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $400.00 price objective on the health services provider’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 11.86% from the stock’s current price.

Several other equities research analysts have also commented on CI. Piper Sandler assumed coverage on shares of The Cigna Group in a report on Wednesday, June 26th. They issued an “overweight” rating and a $400.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $384.00 price target on shares of The Cigna Group in a research note on Monday. StockNews.com raised shares of The Cigna Group from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Stephens reaffirmed an “overweight” rating and issued a $410.00 price target on shares of The Cigna Group in a research note on Friday, August 2nd. Finally, Barclays raised their target price on shares of The Cigna Group from $393.00 to $405.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $387.00.

The Cigna Group Stock Performance

Shares of NYSE CI traded down $0.01 during mid-day trading on Tuesday, hitting $357.60. The stock had a trading volume of 164,868 shares, compared to its average volume of 1,530,879. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.71 and a current ratio of 0.71. The company has a 50 day moving average of $341.24 and a two-hundred day moving average of $343.72. The Cigna Group has a twelve month low of $253.95 and a twelve month high of $370.64. The firm has a market cap of $99.97 billion, a PE ratio of 29.35, a PEG ratio of 1.08 and a beta of 0.50.

The Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, August 1st. The health services provider reported $6.72 EPS for the quarter, beating the consensus estimate of $6.42 by $0.30. The Cigna Group had a net margin of 1.70% and a return on equity of 17.83%. The company had revenue of $60.52 billion for the quarter, compared to analyst estimates of $58.30 billion. During the same period in the prior year, the company earned $6.13 earnings per share. The firm’s revenue was up 24.6% on a year-over-year basis. Research analysts predict that The Cigna Group will post 28.48 EPS for the current fiscal year.

Insider Buying and Selling at The Cigna Group

In other news, insider Brian C. Evanko sold 4,795 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $345.01, for a total value of $1,654,322.95. Following the completion of the sale, the insider now directly owns 39,923 shares of the company’s stock, valued at $13,773,834.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other The Cigna Group news, Director Elder Granger sold 1,000 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $338.08, for a total transaction of $338,080.00. Following the transaction, the director now directly owns 5,471 shares in the company, valued at $1,849,635.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian C. Evanko sold 4,795 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $345.01, for a total transaction of $1,654,322.95. Following the completion of the sale, the insider now owns 39,923 shares in the company, valued at $13,773,834.23. The disclosure for this sale can be found here. Insiders sold 9,033 shares of company stock worth $3,095,820 over the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On The Cigna Group

Large investors have recently bought and sold shares of the stock. Capital Asset Advisory Services LLC increased its stake in The Cigna Group by 2.3% during the 1st quarter. Capital Asset Advisory Services LLC now owns 1,280 shares of the health services provider’s stock worth $464,000 after buying an additional 29 shares during the period. Checchi Capital Advisers LLC lifted its position in The Cigna Group by 0.9% in the 2nd quarter. Checchi Capital Advisers LLC now owns 3,584 shares of the health services provider’s stock valued at $1,185,000 after purchasing an additional 31 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in The Cigna Group by 1.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,206 shares of the health services provider’s stock valued at $729,000 after purchasing an additional 31 shares during the last quarter. Capital Advisors Ltd. LLC raised its position in shares of The Cigna Group by 10.6% during the 1st quarter. Capital Advisors Ltd. LLC now owns 335 shares of the health services provider’s stock worth $122,000 after buying an additional 32 shares in the last quarter. Finally, Capital Investment Advisors LLC raised its position in shares of The Cigna Group by 2.9% during the 2nd quarter. Capital Investment Advisors LLC now owns 1,122 shares of the health services provider’s stock worth $371,000 after buying an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 86.99% of the company’s stock.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.